Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma

E-ISSN： 1099-1069|36|1|238-244

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 238-244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib: A Review of its Use in Patients with Multiple Myeloma

By Curran Monique P. McKeage Kate

Drugs, Vol. 69, Iss. 7, 2009-05 ,pp. : 859-888

Adis International

Access to resources Recommend Favorite

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma

By Hellmann Andrzej

Clinical Pharmacokinetics, Vol. 50, Iss. 12, 2011-12 ,pp. : 781-791

Adis International

Access to resources Recommend Favorite

Bortezomib‐induced peripheral neuropathy: A genome‐wide association study on multiple myeloma patients

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 232-237

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib in multiple myeloma

By Terpos Evangelos Roussou Maria Dimopoulos Meletios-Athanassios

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib for multiple myeloma

By Popat Rakesh Joel Simon Oakervee Heather Cavenagh Jamie

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite